Breast Cancer
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy while Personalis completes its clinical validation in more indications.
Mass General Tries to Show Value of Virtual Precision Medicine Clinic to Community Oncologists
Premium
The virtual clinic helped community oncologists interpret genomic testing results and led a third of cases to be enrolled in precision medicine drug trials.
FDA Approves AstraZeneca's Truqap in HR-Positive, HER2-Negative Breast Cancer
The drug is approved for breast cancer patients with PIK3CA, AKT1, or PTEN alterations as determined by a companion diagnostic test.
The firm believes its investigational antibody-drug conjugate Dato-DXd could replace chemotherapy in certain breast and lung cancer treatment settings.
Gilead Reports 57 Percent Jump in Trodelvy Sales in Q3, Doubles Down on Anti-TIGIT Aspirations
Premium
Oncology product sales climbed 33 percent during the third quarter of this year, though overall sales remained flat compared to Q3 2022.